Lori Blackmer
Optometrist · Picayune, MSNPI 1760451595
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (54.1%), travel and lodging and education — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Carl Zeiss Meditec USA, Inc. at 49.2% of the total. Reporting peaked in 2023 at $2,583 and has fallen 73.8% since, to $678 in 2025. Among optometrist clinicians in MS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 103 payments — averaging $42.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Carl Zeiss Meditec USA, Inc.$2K
- Oyster Point Pharma, Inc.$390
- Alcon$385
- Bausch & Lomb Americas Inc.$377
- AbbVie$223
- Dompe US, Inc.$154
- plus $687 from 12 others
What the payments were for
- Travel & lodging$1,90244%
- Food & beverage$2,35954%
- Education$1002%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Carl Zeiss Meditec USA, Inc. | 3 | $2,145 |
| Oyster Point Pharma, Inc. | 15 | $390 |
| Alcon | 20 | $385 |
| Bausch & Lomb Americas Inc. | 19 | $377 |
| AbbVie(2 entities) | 11 | $223 |
| Dompe US, Inc. | 5 | $154 |
| Mallinckrodt Hospital Products Inc. | 2 | $115 |
| Coopervision Inc. | 5 | $96 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $92 |
| Sun Pharmaceutical Industries Inc. | 4 | $86 |
| Novartis | 4 | $69 |
| Tarsus Pharmaceuticals, Inc. | 2 | $55 |
| Apellis Pharmaceuticals, Inc. | 1 | $52 |
| Aerie Pharmaceuticals, Inc. | 2 | $37 |
| Tearlab Corp | 2 | $33 |
| Kala Pharmaceuticals, Inc. | 1 | $22 |
| Eyevance Pharmaceuticals LLC | 1 | $16 |
| Glaukos Corporation | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CLARUS$4,133
- CIRRUS HD-OCT$2,067
- FORUM$2,067
- Humphrey Field Analyzer (HFA3)$2,067
How this compares
$4,361 in reported general payments places this provider in the 90th percentile of 372 optometrist providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 82 | $106,834 |
| LumiganBimatoprost | 61 | $24,482 |
| Cyclosporine | 21 | $9,979 |
| VyzultaLatanoprostene Bunod | 13 | $8,420 |
| XiidraLifitegrast | 12 | $8,116 |
| Fluorometholone | 80 | $4,790 |
| Loteprednol Etabonate | 31 | $3,466 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 37 | $1,946 |
| Prednisolone Acetate | 45 | $1,833 |
| Latanoprost | 321 | $1,795 |
| ErythromycinErythromycin Base | 159 | $1,548 |
| Timolol Maleate | 122 | $1,126 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 57 | $654 |
| Doxycycline Monohydrate | 16 | $233 |
| Brimonidine Tartrate | 42 | $225 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $223 | $131,315143 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra | $377 | $16,53625 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $92 | $3,46631 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 372 optometrist providers in Mississippi.
Other optometrist in Picayune
- Kristopher MayColdwater$229K
- Alyssa MabrySenatobia$66K
- Roya AttarJackson$19K
- Deandre CarrByram$9K
- Michael ObrienSouthaven$9K
- George MarchbanksGulfport$9K
- William ArnoldMadison$9K
- Ramonica LewisClinton$8K
- Megan LottHattiesburg$8K
- Hal HillMadison$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.